Are Androgen Receptor Variants a Substitute for the Full-Length Receptor?

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10.

Abstract

Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Publication types

  • Review

MeSH terms

  • Alternative Splicing
  • Animals
  • Disease Progression
  • Gene Expression Profiling
  • Gene Expression Regulation / physiology
  • Humans
  • Male
  • Neoplasms, Hormone-Dependent
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • Protein Isoforms
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*
  • Signal Transduction / physiology

Substances

  • Protein Isoforms
  • Receptors, Androgen